We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA and CMS Clarify Their Roles in Wake of Aduhelm Decision on Medicare Access
FDA and CMS Clarify Their Roles in Wake of Aduhelm Decision on Medicare Access
The FDA and Centers or Medicare and Medicaid Services (CMS) took the rare step Friday of issuing a joint statement to clarify their regulatory authorities one day after the CMS made a controversial decision on who will have Medicare-paid access to the Alzheimer’s drug Aduhelm (aducanumab).